3 FTSE AIM Pharma Stocks That Have Given Returns of Over 100% In a Year

3 min read | May 13, 2021 02:01 PM BST | By Suhita Poddar

Google News:

Recent News

Telix Pharmaceuticals (ASX:TLX): Why Is Radiopharma Proof In Focus?

Woodside Energy (ASX:WDS): What Does Energy Momentum Show?

Xero (ASX:XRO): Why Is The Tech Trend Tested?

Plenti Group (ASX:PLT): Why Is Smallcap Lending In View?

Make Kalkine Media
My Trusted Source

Summary

Vaccine related stocks have gained a lot of attention due to the pandemic; however other pharmaceutical and biotechnology stocks have faced volatility.

The focus has been primarily on companies having high levels of research and development capabilities.

Pharmaceuticals and biotechnology stocks have gained attention in recent times, especially vaccine related stocks, due to their contribution in the fight against the pandemic. But, aside from pharma giants, the rest of the pharmaceutical and biotechnology sector has been facing some extent of volatility as the focus has been primarily on companies having high levels of research and development capabilities, among other factors.

In this article, we would take a look at 3 FTSE AIM All Share stocks in the pharmaceuticals and biotechnology sector that have given returns of over 100 per cent:

Agronomics Ltd (LON:ANIC)

FTSE AIM All Share listed biotechnology firm Agronomics is UK’s leading listed alternative protein company. Today it announced a secondary purchase of shares in Dutch food production company Meatable.

Agronomics bought a further 117 shares worth EUR 195,632, which now brings its shareholding to 4,859 shares in Meatable and equity ownership of 5.84 per cent in the meat company.

(Source: EODHD/Others, Thomson Reuters)

The company’s shares were trading at GBX 23.90, down by 0.42 per cent as of 13 May at 10:37 hrs GMT+1, while the medicine and biotech sectoral index stood at 16,240.09, down by 1.00 per cent.

Agronomics has a current market capitalisation of £120.45 million and a one-year return of 258.15 per cent.

Also Read: A Glance at 5 Healthcare Penny Stocks

E-Therapeutics PLC (LON:ETX)

E-Therapeutics came up with its final audited results for FY 2021 ending 30 January today.

The company reported that its revenues fell to £0.3 million from £0.5 million in FY 2020, while its operating losses improved from £2.9 million in FY 2020 to £4.5 million in FY 2021. It also raised total gross funds worth up to £13.2 million in the FY2021.

(Source: EODHD/Others, Thomson Reuters)

The company’s shares were trading at GBX 27.00, down by 6.25 per cent as of 13 May at 10:34 hrs GMT+1, while the broader index FTSE AIM All Share stood at 1,215.10, down by 1.42 per cent.

E-Therapeutics has a current market capitalisation of £121.18 million, and its one-year return stood at 104.87 per cent.

Also Read: Five Healthcare Stocks to Consider- Synairgen, Novacyt, Avacta Group, Okyo Pharma, and E-Therapeutics

Sareum Holdings PLC (LON:SAR)

UK based Sareum Holdings is also listed on the FTSE AIM All share index. The drug discovery company mainly focuses on cancer related small molecule therapeutics. Sareum announced on 13 May exercised share options for over 3,000,000 new ordinary shares worth 0.25 pence per share and with an exercise price of 0.6 pence per share.

(Source: EODHD/Others, Thomson Reuters)

The company’s shares were trading at GBX 2.38, down by 3.06 per cent as of 13 May at 10:42 hrs GMT+1. Sareum Holdings has a current market capitalisation of £80.06 million and a one-year return of 203.25 per cent.

Also Read: Quick Review of Two AIM Listed Stocks: Altus Strategies PLC & Sareum Holdings PLC

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.